Clinical Trial Update: A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Phase II, single-arm study of BGJ398 in advanced cholangiocarcinoma with FGFR2 mutation was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• BGJ398 (BGJ398)

Snippet

Sponsor: QED Therapeutics, a BridgeBio company | Conditions: Advanced Cholangiocarcinoma, FGFR2 Gene Mutation | Phase 2 | Status: TERMINATED | Results posted: 2022-07-15